Global Finance News
30 Apr 2026, 17:13
Regeneron Pharmaceuticals reported strong first-quarter 2026 results, driven by robust product growth and continued pipeline expansion.
Revenue increased 19% year-over-year to $3.6 billion, reflecting solid demand across key therapies. Non-GAAP EPS reached $9.47, while GAAP EPS was $6.75, impacted by charges related to in-process R&D.
Growth was supported by Dupixent, whose global sales (reported by partner Sanofi) surged 33% to $4.9 billion. Meanwhile, EYLEA HD U.S. sales jumped 52% to $468 million, although combined EYLEA franchise sales declined 10%, reflecting product transition dynamics.
On the regulatory front, the company secured multiple approvals, including expanded indications for Dupixent and the approval of Otarmeni, a first-in-class gene therapy for genetic hearing loss.
Regeneron also announced a new $3 billion share buyback program, underscoring confidence in its long-term growth outlook.
Source: GlobeNewswire
Revenue increased 19% year-over-year to $3.6 billion, reflecting solid demand across key therapies. Non-GAAP EPS reached $9.47, while GAAP EPS was $6.75, impacted by charges related to in-process R&D.
Growth was supported by Dupixent, whose global sales (reported by partner Sanofi) surged 33% to $4.9 billion. Meanwhile, EYLEA HD U.S. sales jumped 52% to $468 million, although combined EYLEA franchise sales declined 10%, reflecting product transition dynamics.
On the regulatory front, the company secured multiple approvals, including expanded indications for Dupixent and the approval of Otarmeni, a first-in-class gene therapy for genetic hearing loss.
Regeneron also announced a new $3 billion share buyback program, underscoring confidence in its long-term growth outlook.
Source: GlobeNewswire
